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A B S T R A C T   
Catalyzed by zDHHC-PAT enzymes and reversed by thioesterases, protein palmitoylation is the only post- 
translational modification recognized to regulate the sodium/calcium exchanger NCX1. NCX1 palmitoylation 
occurs at a single site at position 739 in its large regulatory intracellular loop. An amphipathic ɑ-helix between 
residues 740–756 is a critical for NCX1 palmitoylation. Given the rich background of the structural elements 
involving in NCX1 palmitoylation, the molecular basis of NCX1 palmitoylation is still relatively poorly under-
stood. Here we found that (1) the identity of palmitoylation machinery of NCX1 controls its spatial organization 
within the cell, (2) the NCX1 amphipathic ɑ-helix directly interacts with zDHHC-PATs, (3) NCX1 is still pal-
mitoylated when it is arrested in either Golgi or ER, indicating that NCX1 is a substrate for multiple zDHHC- 
PATs, (4) the thioesterase APT1 but not APT2 as a part of NCX1-depalmitoylation machinery governs subcel-
lular organization of NCX1, (5) APT1 catalyzes NCX1 depalmitoylation in the Golgi but not in the ER. We also 
report that NCX2 and NCX3 are dually palmitoylated, with important implications for substrate recognition and 
enzyme catalysis by zDHHC-PATs. Our results could support new molecular or pharmacological strategies tar-
geting the NCX1 palmitoylation and depalmitoylation machinery.   
1. Introduction 
The cardiac Na+/Ca2+ exchanger (NCX1) regulates cytosolic Ca2+
levels in myocytes and therefore cardiac contractility by controlling the 
bidirectional transport of Na+ and Ca2+ ions across the surface mem-
brane. In healthy myocardium, NCX1 mainly generates an inward Na+
current and extrudes Ca2 (1 Ca2+: 3 Na+) [1,2]. Inappropriate NCX1 
activity is associated with a number of severe cardiac pathologies 
including myocardial infarction [3], heart failure [4] and arrhythmias 
[5,6]. 
Multiple regulatory mechanisms control NCX1. Two calcium binding 
domains (CBDs) in the large regulatory loop (Fig. 1A) facilitate allosteric 
regulation of NCX1 by intracellular calcium [7]. Calcium binding to 
CBD1 activates NCX1, while calcium binding to CBD2 opposes NCX1 
inactivation [8,9]. The endogenous XIP domain, at the N terminal end of 
the same regulatory loop (Fig. 1A), inhibits NCX1 [10] but is usually 
sequestered by the phospholipid PIP2 [11]. Reversible palmitoylation is 
a key regulator of NCX1 activity [12,13] because it sensitizes NCX1 to 
XIP, and hence to PIP2, leading to enhanced NCX1-mediated trans-
membrane Ca flux when NCX1 is non-palmitoylated [14]. This effect of 
palmitoylation on NCX1 inactivation occurs without an apparent impact 
on the ability of calcium to activate NCX1 [15]. However, it is notable 
that the close proximity of CBD2 (502–690) to the XIP binding (709–720 
[14]) and palmitoylation (C739) sites means that the conformational 
flexibility of the entire C terminal half of the NCX1 regulatory loop may 
change according to Ca occupancy of CBD2, whether XIP is sequestered 
by PIP2, and whether C739 is palmitoylated [7]. Hence understanding 
the cellular control of NCX1 palmitoylation is a high priority. 
Palmitoylation relies on the direct conjugation of a fatty acid (usually 
16C palmitic acid) onto cysteine residue(s) of a target protein via thio-
ester bond [16]. This dynamic modification is catalyzed by a group of 
enzymes, called protein acyl-transferases (PATs), with a unique cysteine 
rich zinc-finger containing Asp-His-His-Cys (zDHHC) motif and reversed 
by depalmitoylating enzymes including acyl-protein thioesterases 
(APTs; APT1 and APT2) and lysosomal palmitoyl-protein thioesterases 
(PPTs; PPT1 and PPT2). NCX1 has one palmitoylated cysteine, which 
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sits at the position 739 at the C terminal end of its large regulatory 
intracellular loop, close to the XIP binding site [14]. A single mutation 
from cysteine to alanine (C739A) at this position abolishes NCX1 pal-
mitoylation [12,15,17,13]. An amphipathic ɑ-helix structure directly 
adjacent to the palmitoylated cysteine is required for palmitoylation of 
the exchanger [18,19]; however, how this particular structure, residing 
between residues 740 and 756, controls NCX1 palmitoylation remains 
unclear. 
Given the structural insights into the underlying mechanism of NCX1 
palmitoylation reported so far, our knowledge on enzymatic regulation 
of NCX1 palmitoylation is limited to the recent discovery of zDHHC5 
and APT1 mediated palmitoylation and depalmitoylation of the 
exchanger [14]. zDHHC5 was found to interact with the exchanger and 
act as a sensor regulating the dynamic changes in NCX1 palmitoylation 
and therefore palmitoylation dependent structural re-arrangement 
within the NCX1 dimer. NCX1 palmitoylation in zDHHC5 KO cells was 
diminished, but not completely lost, which implies roles for multiple 
zDHHC-PATs in NCX1 palmitoylation [14]. 
Despite the considerable importance of palmitoylation in NCX1 
physiology, there are still missing pieces regarding molecular specificity 
of NCX1 palmitoylation. In this study, we set out to investigate the 
spatial control of NCX1 palmitoylation, and how in turn this controls 
NCX1 localisation. We report that by interacting with the NCX1 palmi-
toylating enzymes, the amphipathic α-helix responsible for NCX1 pal-
mitoylation directs the subcellular distribution of NCX1. By arresting 
NCX1 in intracellular compartments we determine that it is a substrate 
for both ER and Golgi-resident zDHHC-PATs. We also find that the same 
the amphipathic α-helix responsible for NCX1 palmitoylation directs 
dual palmitoylation of NCX2 and NCX3. Finally we report that ATP1 but 
not APT2 controls the spatial organisation of NCX1 in the cell, but that it 
is unable to depalmitoylate NCX1 in the ER. Our findings defining the 
molecular nature of NCX1 palmitoylation have important implications 
in the design of pharmacological tools to target NCX1 palmitoylation to 
cope with cardiac pathologies associated with abnormal exchanger 
activity. 
Fig. 1. Tracking subcellular localization of NCX1 palmitoylation machinery. 
(A) Schematic of NCX1 structure equipped with 10 T M and a large intracellular loop accommodating Exchanger Inhibitory Peptide (XIP), Calcium Binding Domains 
(CBDs: CBD1 and CBD2) and palmitoylation site, (B) Example confocal images demonstrating localization of full length NCX1, NCX1266–765 and NCX1690–765 in 
HEK293 cells, (C, D) Both NCX1266–765 and NCX1690–765 colocalized with Golgi and ER (Pearson’s coefficient: 0.83 ± 0.0094 (SEM) for NCX1266–765/Golgi (n: 70) and 
0.73 ± 0.017 (SEM) for NCX1266–765/ER (n: 50); 0.833 ± 0.013 (SEM) for NCX1690–765/Golgi (n: 38) and 0.70 ± 0.022 (SEM) for NCX1690–765/ER (n: 32)). Golgi 
localization of both NCX1 fragments were significantly greater than those localized in ER (unpaired t-test: p-value: <0.0001 for NCX1266–765/Golgi vs NCX1266–765/ 
ER and NCX1690–765/Golgi vs NCX1690–765/ER, calculated by unpaired t-test) (E, F) Either breaking the ɑ-helix structure (M744 P/H745 P/F746 P) or introducing 
negatively charged aa in hydrophobic part of amphipathic helix (F746E/F750E) disrupted both palmitoylation and intracellular compartmentalization of NCX1. UF: 
unfractionated cell lysate; Palm: purified palmitoylated proteins. Scale bars: 5 μm. 
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2. Results 
2.1. The palmitoylation machinery of NCX1 determines its subcellular 
localization 
NCX1 architecture consists of 10 T M domains and a large intracel-
lular loop positioned between TM5 and 6, which harbours 3 functionally 
key components: 20aa long XIP peptide, two CBDs and the palmitoyla-
tion site (Fig. 1A). Here, we first asked if we can track palmitoylated 
NCX1 in the cell via its palmitoylation site. Full length canine NCX1 
tagged with YFP at position 266; NCX1266Y, [20] (left, Fig. 1B) and YFP- 
tagged NCX1 truncations corresponding to residues 266–765 
(NCX1266–765) covering the CBDs and palmitoylation site (middle, 
Fig. 1B) and residues 690–765 (NCX1690–765) with only the palmitoy-
lation site (right, Fig. 1B), were expressed in HEK293 cells. While NCX1 
was situated at the cell surface when the TM domains are present in the 
structure, both truncations were populated in distinct intracellular 
puncta in the cells (Fig. 1B) which indicates that the palmitoylated state 
is retained in distinct compartment(s) in the absence of TM domains. We 
next hypothesized that NCX1 fragments containing the palmitoylation 
site are compartmentalized at intracellular organelles such as Golgi and 
Endoplasmic Reticulum (ER), where palmitoylating enzymes are 
Fig. 2. NCX1 interacts with zDHHC-PATs 
through its amphipathic ɑ-helix. 
(A) Example blots of zDHHC-PATs purified by 
custom made peptide corresponding to ɑ-helix 
structure of NCX1 (NCX1740–756) (B) All DHHC 
isoforms were pulled down with different pro-
pensities by the NCX1 peptide. (C) Sequence 
comparison of NCX1, NCX2 and NCX3. Acyl 
PEG exchange indicates single palmitoylation 
of NCX1 but dual palmitoylation of NCX2 and 
NCX3. EV: empty vector transfected cells; UF: 
unfractionated cell lysate; PEG: acyl PEG 
exchange.   
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abundant. We therefore co-expressed NCX1 fragments; either 
NCX1266–765 or NCX1690–765, with either Golgi (Grasp65-mcherry) or ER 
(DsER-red) markers (Fig. 1C), then analysed and quantified the degree of 
co-localization (Fig. 1D). Both fragments; NCX1266–765 and NCX1690–765, 
displayed a notable degree of spatial overlap with Golgi and ER markers. 
However the degree of co-localization with the Golgi marker was 
significantly greater than the ER marker for both NCX1 fragments 
(p-value: <0.0001 for NCX1266–765/Golgi vs NCX1266–765/ER and 
NCX1690–765/Golgi vs NCX1690–765/ER, calculated by unpaired t-test). In 
separate experiments we obtained similar results when we examined 
colocalization of NCX1266–765 with HA-tagged Golgin-84 (Golgi marker) 
or HA-tagged Ii (ER marker) (Supplementary Fig. 1). 
Data herein support the notion that the subcellular organization of 
the NCX1 intracellular loop is controlled by its palmitoylation machin-
ery. To prove the concept of “palmitoylation machinery” dependent 
subcellular distribution of NCX1, we investigated how NCX1266–765 
localization is altered when its palmitoylation is drastically abolished by 
either (1) breaking the amphipathic ɑ-helix that is required for NCX1 
palmitoylation (M744 P/H745 P/F746 P) or (2) introducing negatively 
charged aa; Glu- (E), to position 746 and 750 in hydrophobic part of the 
ɑ-helix (F746E/F750E) (Fig. 1E), or (3) incubating with a broad pal-
mitoylating enzyme inhibitor, 2-Bromopalmitate (2-BP) [18,14,19]. 
NCX1 is no longer palmitoylated when either M744 P/H745 P/F746 P or 
F746E/F750E mutations are introduced (Fig. 1E). All experimental 
strategies aiming to prevent the formation of palmitoylation complex of 
NCX1 disrupted its organelle-specific retention (Fig. 1F). 
2.2. The amphipathic ɑ-helix of NCX1 interacts with zDHHC-PATs 
Given the detailed knowledge regarding the structural organization 
of the NCX1 palmitoylation site, how NCX1 gets palmitoylated still re-
mains unclear. The amphipathic ɑ-helix that is next to palmitoylated 
cysteine (C739) was previously identified as the “control unit” of NCX1 
palmitoylation [18,19]. We asked if this ɑ-helix, corresponding to 
740–756aa residues of NCX1 intracellular loop, is the structural 
component that interacts with palmitoylating zDHHC-PAT enzymes. 
Therefore, we transfected HEK293 cells with HA tagged zDHHC iso-
forms (24 isoforms), then purified the protein acyltransferases that are 
associated with NCX1 using a biotinylated custom-made ɑ-helix 
(NCX1740–756) peptide from cell lysates. Strikingly, we pulled down all 
zDHHC isoforms with different propensities to bind to the ɑ-helix pep-
tide (Fig. 2A). It is thus conceivable that amphipathic helix may be 
recognized by a specific sequence/motif that can be found in all DHHC 
isoforms. zDHHC5 is the only palmitoylating enzyme reported to 
interact with NCX1 to date [14]. Apart from zDHHC5, several Golgi- 
(zDHHC3, zDHHC4, zDHHC7, zDHHC8, zDHHC15, zDHHC17 and 
zDHHC18), ER- (zDHHC1, zDHHC11, zDHHC13, zDHHC14, zDHHC16 
and zDHHC19) and Golgi/ER- (zDHHC2, zDHHC9, zDHHC12 and 
zDHHC22) located protein acyl-transferases [21–27] were highly asso-
ciated with ɑ-helix peptide (Fig. 2B). This strongly supports our findings 
that formation of the NCX1-palmitoylation complex requires the asso-
ciation between the amphipathic helix of the exchanger and Golgi, ER or 
Golgi/ER resident palmitoylating enzymes. 
2.3. NCX2 and NCX3 are dually palmitoylated 
Given our finding that the palmitoylation-directing NCX1 helix in-
teracts with the zDHHC-PAT(s), we turned our attention to the same 
region of NCX2 and NCX3. These transporters both possess a cysteine in 
the equivalent position to C739, followed by the identical amphipathic α 
helix with a second cysteine at its C terminal end (position F757 in 
NCX1, Fig. 2C). We used a PEGylation assay, which exchanges palmi-
tates for a 5 kDa PEG molecule, to measure the palmitoylation stoichi-
ometry of F757C NCX1 and found it to be dually palmitoylated. Hence 
the zDHHC-PATs that recognise this structural element are capable of 
palmitoylating cysteines at either end of the helix. 
2.4. NCX1 is palmitoylated even when it is arrested in either Golgi or ER 
Based on our data presented here which dissected the interacting 
zDHHC-PATs of NCX1, we hypothesized that NCX1 can be palmitoylated 
in both the Golgi and the ER. To test our hypothesis, we employed 
Retention Using Selective Hook (RUSH) System [28]. RUSH system was 
originally introduced to analyse and quantify the trafficking of various 
proteins in live cells. This system is, in principle, a two-state assay which 
relies on the interaction between the hook, stably expressed in the 
intracellular compartment of interest, and Streptavidin Binding Protein 
(SBP) fused- reporter (Fig. 3A). Herein we adapted and re-purposed 
RUSH to further our understanding of the relationship between NCX1 
and its palmitoylating enzymes. We generated two critical components 
of RUSH system: (1) SBP fused- full length canine NCX1 tagged with YFP 
at position 266 (NCX1266Y) (Fig. 3B), and (2) cell lines stably expressing 
either Golgi (Streptavidin-HA-Golgin84) or ER (Streptavidin-HA-Ii) 
hooks. We tested if SBP insertion into NCX1 causes any changes in 
subcellular localization of NCX1 and we found that fusing SBP to NCX1 
had no effect on cellular distribution of (full length) NCX1 in HEK293 
cell; localized through plasma membrane as expected (Fig. 3B). 
HA-tagged hook proteins displayed classic ER and Golgi localisation 
(Fig. 3C). When SBP-NCX1 was expressed in either Golgi- or ER- hook 
cells, it was predominantly observed in the same compartment as the 
hook (Fig. 3D). These validate the reliability and the suitability of our 
RUSH system for the aim of this study. Finally we measured the pal-
mitoylation level of NCX1 in both Golgi- and ER-hook cells to check if 
NCX1 is palmitoylated when it is restricted in either cellular compart-
ment (Fig. 3D). We found that NCX1 was equally palmitoylated 
regardless of whether its expression was limited to either intracellular 
compartment. 
2.5. Depalmitoylation machinery of NCX1 
We recently identified that APT1 but not APT2 interacts with NCX1 
by LC–MS/MS following peptide purification from heart and brain tis-
sues [14]. Furthermore, pharmacologically impeding APT1 activity in 
cells increased palmitoylated NCX1 levels and FRET signals between 
NCX1 pairs. Here, we tested if we can probe the activity of depalmi-
toylation machinery of NCX1 in the cell using its palmitoylation site. A 
YFP tagged NCX1 fragment covering palmitoylation site; NCX1266–765, 
was over-expressed in HEK293 cells together with either APT1- or APT2- 
tagged with CFP, or alone as a control. In order to detect the activity of 
depalmitoylation machinery of NCX1, we first calculated the size of the 
compartmentalized NCX1 population in the cell in proportion to the 
total cell size for each cell (Fig. 4A). Using fluorescent markers of the 
Golgi and ER, we calculated the area of palmitoylated NCX1 in the Golgi 
or ER separately, in the presence and absence of APT1 or APT2 over-
expression. The size of the Golgi-localized puncta containing the pal-
mitoylated NCX1 (fragment) was significantly smaller in the cells 
over-expressing APT1 than control group. In contrast, over-expressing 
APT2 did not alter the size of populated NCX1 in Golgi in comparison 
to control group (Fig. 4B). This implies that over-expression of APT1 
promoted NCX1 depalmitoylation, therefore reduced the amount of 
palmitoylated NCX1 which is compartmentalized in the Golgi. To vali-
date this, we next assessed Golgi co-localization of NCX1 after either 
APT1 or APT2 over-expression (Fig. 4C, D). HEK293 cells were trans-
fected with NCX1266–765 alone or together with either APT1 or APT2. 
Over-expression of APT1 but not APT2 caused less Golgi co-localization 
of NCX1 than the control group. We conclude that the enhanced NCX1 
depalmitoylation caused by APT1 over-expression in these cells dimin-
ished the amount of palmitoylated NCX1 localized in the Golgi. 
Next we considered the population of palmitoylated NCX1 fragment 
found localized in the ER. Overexpression of neither APT1 nor APT2 
altered the size of NCX1 puncta in this compartment (Fig. 5A, B). Nor did 
expression of APT1 or APT2 alter the colocalization of NCX1 with an ER 
marker (Fig. 5A, C). This suggests that APT1 only depalmitoylates NCX1 
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when it is in the Golgi. 
3. Discussion 
Palmitoylation is a critical regulator of NCX1 function [14], yet 
relatively little is known about the cellular mechanisms controlling 
NCX1 palmitoylation. Detailed mutation screening around the palmi-
toylation site has earlier described two crucial components of NCX1 
palmitoylation: (1) the palmitoylated Cys- at position 739 [15], and (2) 
an amphipathic helix; a secondary structure element sitting between 
position 740 and 756 [18,19]. Here, we uncover the molecular identity 
of the NCX1 palmitoylation machinery using an intersectional approach. 
We also demonstrate that the palmitoylation-depalmitoylation cycle 
controls the spatial organization of NCX1 in the cell. 
Fig. 3. Establishing RUSH system to identify organelle specific NCX1 palmitoylation machinery. 
(A) Schematic illustrating the design of NCX1-RUSH system (B) SBP fusion to NCX1 did not alter the cellular distribution of NCX1. Scale bar: 10μm (C) Immu-
nostained confocal images of HA-tagged hooks in Golgi-Hook and ER-Hook cell lines. Scale bar: 20 μm (D) Confocal imaging confirms that SBP-NCX1 (green) is 
retained in the appropriate cellular compartment when it is expressed in cells expressing Golgi or ER hooks. Scale bar: 10 μm (E) NCX1 is palmitoylated when it is 
retained in either Golgi or ER by RUSH (Palmitoylation level of NCX1 relative to its expression: 1.12 ± 0.05 (SEM) in HEK293 cells (n:10), 1.39 ± 0.02 (SEM) in Golgi 
Hook cells (n: 4) and 1.14 ± 0.05 (SEM) in ER Hook cells (n: 7); Unpaired t-test: HEK293 vs Golgi Hook p-value: 0.34; HEK293 vs ER Hook p-value:0.95; Golgi Hook 
vs ER Hook p-value: 0.23). 
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3.1. Spatial control of NCX1 palmitoylation 
We first noted that NCX1 fragments (either NCX1266–765 or 
NCX1690–765) covering the palmitoylation site are compartmentalized in 
both Golgi and ER. Our previous investigations identified the Golgi as 
the main cellular location in which NCX1266–765 became localised [15, 
18,19], in keeping with the role of the Golgi as the cellular palmitoy-
lation ‘hub’ [29,30]. In the present study, we confirmed the greatest 
quantitative overlap of palmitoylated NCX1 is with a Golgi marker, but 
that a significant proportion of palmitoylated NCX1 is also in the ER. 
Fig. 4. The activity of APT1 but not APT2 diminished the amount of palmitoylated NCX1 in Golgi and colocalization of NCX1/Golgi. 
(A) Steps for image analysis to quantify the size of “compartmentalized NCX1′′ in the cell, Scale bar:10 μm (B) APT1 but not APT2 altered the size of NCX1 puncta in 
the Golgi (Golgi: 27.03 % ±1.86 (SEM) for NCX1266–765 only (n: 70), 15.57 % ±1.96 (SEM) for NCX1266–765/APT1 (n: 61), 24.26 % ±2.09 (SEM) for NCX1266–765/ 
APT2 (n: 73); unpaired t-test: NCX1266–765 only vs NCX1266–765/APT1 p-value: 0.0003 and NCX1266–765 only vs NCX1266–765/APT2 p-value: 0.363). (C, D) Golgi 
colocalization of NCX1 was diminished when APT1 but not APT2 was expressed (Pearson’s coefficient: 0.83 ± 0.0094 (SEM) for NCX1266–765 only/Golgi (n: 70); 0.75 
± 0.015 (SEM) for NCX1266–765 +APT1/Golgi (n: 61) and 0.81 ± 0.01 (SEM) for NCX1266–765 +APT2/Golgi (n: 73); p-values: 0.0001 for NCX1266–765 only vs 
NCX1266–765 +APT1; 0.0023 for NCX1266–765 +APT1 vs NCX1266–765 +APT2 and 0.17 for NCX1266–765 only vs NCX1266–765 +APT2, calculated by unpaired t-test). 
Scale bar:10 μm. 
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This implies that the NCX1 palmitoylation site is recognised by both 
Golgi and ER- located zDHHC-PATs and that the NCX1 fragment gets 
anchored to the membrane following its palmitoylation. Supporting this, 
abolishing NCX1 palmitoylation by disrupting the palmitoylation ma-
chinery of the exchanger; either using broad inhibitor of palmitoylating 
enzymes; 2-BP, or breaking the ɑ-helix structure by M744 P/H745 
P/F746 P or F746E/F750E, prevented this particular distribution of 
NCX1 in these compartments. Secondly, we found a peptide represent-
ing the NCX1 amphipathic helix interacts physically with Golgi, ER and 
Golgi/ER located palmitoylating enzymes. Third, with the help of RUSH 
system, we detected NCX1 to be equally palmitoylated when it is 
confined in either Golgi or ER. What do these observations tell us? The 
important take-home message here is that substrate recognition by 
zDHHC-PATs occurs at the ɑ-helix structure within the NCX1 intracel-
lular loop, and NCX1 can be palmitoylated locally in either Golgi or ER 
which is determined by the nature of palmitoylation complex. The 
notion of local palmitoylation has been previously hypothesised for 
several proteins [31]. We suggest that integral membrane proteins like 
NCX1 can be palmitoylated in multiple compartments by multiple 
zDHHC-PATs. 
It is well-established by several studies that palmitoylating enzymes 
have specific substrate preferences [32–36]. In our experiments, we 
purified numerous zDHHC-PATs with different efficiencies using a bio-
tinylated peptide based on the NCX1 amphipathic ɑ-helix. We speculate 
Fig. 5. APT1 and APT2 did not affect the size of 
compartmentalized NCX1 in ER and colocali-
zation of NCX1/ER. 
(A) Confocal images of HEK293 cells over-
expressing NCX1/ER, NCX1/ER/APT1 and 
NCX1/ER/APT2, Scale bar: 10 μm (B, C) 
Neither APT1 nor APT2 affected the size of the 
NCX1 compartmentalized in ER (ER: 21.97 % 
±1.766 (SEM) for NCX1266–765 only (n: 50), 
21.8 % ±2.134 (SEM) for NCX1266–765/APT1 
(n: 47), 22.08 % ±1.599 (SEM) for 
NCX1266–765/APT2 (n: 52); p-values: 0.881 for 
NCX1266–765 only vs NCX1266–765 +APT1; 0.583 
for NCX1266–765 +APT1 vs NCX1266–765 +APT2 
and 0.723 for NCX1266–765 only vs NCX1266–765 
+APT2, calculated by unpaired t-test) and 
NCX1266–765/ER colocalization (Pearson’s co-
efficient: 0.73 ± 0.018 (SEM) for NCX1266–765 
only/ER (n: 50); 0.69 ± 0.019 (SEM) for 
NCX1266–765 +APT1/ER (n: 47) and 0.71 ±
0.023 (SEM) for NCX1266–765 +APT2/ER (n: 
52); p-values: 0.119 for NCX1266–765 only vs 
NCX1266–765 +APT1; 0.474 for NCX1266–765 
+APT1 vs NCX1266–765 +APT2 and 0.489 for 
NCX1266–765 only vs NCX1266–765 +APT2, 
calculated by unpaired t-test).   
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that this ɑ-helix might be recognized by a motif common to multiple 
zDHHC-PATs, namely the active site. The binding of the zDHHC-PATs to 
this ɑ-helix peptide with different propensities might be due to the dif-
ference in coverage of this specific “ɑ-helix binding motif” in these 
acyltransferases. 
We recently showed that zDHHC5 interacts with and palmitoylates 
NCX1 and alters NCX1-NCX1 FRET as a result of local changes around 
palmitoylation site within the intracellular loop induced by zDHHC5 
mediated palmitoylation [14]. However, we also reported that NCX1 
was still palmitoylated in zDHHC5 KO cells, implying that other 
zDHHC-PATs might involve in NCX1 palmitoylation. The data presented 
here clarify that NCX1 is a substrate for multiple zDHHC-PATs, not only 
for zDHHC5. 
3.2. Enzymatic control of NCX1 palmitoylation 
Our finding that NCX2 and NCX3 are dually palmitoylated at the N 
and C termini of the amphipathic α-helix has important implications for 
both substrate recognition and enzyme catalysis by zDHHC-PATs. The 
fact that the same amphipathic helix can direct palmitoylation of cys-
teines that are 18 residues apart from each other implies that proximity 
but not absolute position relative to this helix governs cysteine palmi-
toylation. This is important because it implies that algorithms that 
attempt to score palmitoylation sites based on their position relative to 
particular amino acids cannot be used to identify palmitoylation sites in 
the same way that they have been successfully used to identify phos-
phorylation sites. 
With respect to catalysis, the ‘lock and key’ model of enzyme catal-
ysis envisions a scenario in which the substrate ‘key’ fits the active site 
‘lock’ in a single conformation. For the same recognition element to 
promote palmitoylation of amino acids so far apart in three dimensional 
space in NCX2 and NCX3 implies the substrate must be presented to the 
active site in a manner that can support palmitoylation in two positions 
(or alternatively that different zDHHC-PATs palmitoylate the cysteines 
at each end of the helix). Again, this contrasts with the behaviour of 
protein kinases, which is generally much more strict. Evidently the 
crystal structure of the zDHHC-PATs has greatly increased our under-
standing of this class of enzymes [37], but a co-crystal structure of a 
zDHHC-PAT with a substrate is a high priority. 
Our finding that NCX1 is palmitoylated immediately after translation 
implies that this regulatory mechanism controls NCX1 activity from very 
early in the lifetime of the protein. Since palmitoylation controls XIP 
sensitivity of NCX1, our results suggest that NCX1 is sensitive to XIP 
throughout its lifetime in the cell. Ultimately the toxicity of NCX1 
mediated cellular Ca overload means understanding the NCX1 regula-
tory mechanisms is a high priority. The complex interplay between 
NCX1 palmitoylation and the ionic (Na, Ca, pH) and phospholipid (PIP2) 
regulatory mechanisms evidently merits further investigation. For 
example, Ca occupancy of CBD2 opposes NCX1 inactivation [8]. The fact 
that palmitoylation promotes XIP binding close to CBD2 [14] and en-
hances the ability of NCX1 to inactivate [15] suggests functional inter-
play between CBD2 and the palmitoylation site may occur. The 
mechanism underlying Na-dependent inactivation remains enigmatic, 
but ultimately involves XIP engaging its binding site [10], so is likely 
regulated by palmitoylation. On the other hand, inhibition of NCX1 by 
reduced intracellular pH involves regions of the exchanger distant from 
the palmitoylation site [38], implying the two regulatory mechanisms 
are likely independent of each other. Leveraging the ability of NCX1 
palmitoylation to protect cells from toxic Ca overload by promoting both 
inactivation and internalisation of NCX1 [15] may hold therapeutic 
promise. Our findings indicate that multiple zDHHC-PATs could be 
targeted to achieve such a goal. The central importance of the NCX1 
amphipathic helix in recruiting both palmitoylating and depalmitoy-
lating machinery will make this goal challenging. 
3.3. Spatial control of NCX1 depalmitoylation 
Data presented in this investigation shows that APT1 but not APT2 
controls subcellular distribution of NCX1. Curiously, although APT1 is 
clearly capable of depalmitoylating NCX1, ER-localized palmitoylated 
NCX1 is unavailable to APT1. We suggest that APT1 is excluded from the 
ER, and that its ability to depalmitoylate NCX1 (and likely other sub-
strates) hinges on their proximity in the same membrane compartment, 
rather than simple diffusion. This contrasts with the suggestion that the 
cytosolic pool of APT1 is responsible for substrate depalmitoylation in 
all membrane compartments [39]. Since APT1 is membrane-anchored 
by palmitoylation near its amino terminus [40], our findings imply 
that (unlike Golgi and plasma membrane zDHHC-PATs) ER-localized 
zDHHC-PATs cannot palmitoylate APT1 to recruit it into the ER. 
Whether other thioesterases depalmitoylate ER-localized substrates re-
mains to be determined. When full-length NCX1 is trapped in the ER its 
palmitoylation level matches the level observed in other cellular com-
partments, despite the fact that it is unavailable to APT1 in the ER. 
Hence, we do not rule out the possibility that NCX1 is a substrate for 
other depalmitoylating enzymes. Overall, our data suggest that the 
switch mechanism between NCX1- palmitoylation and depalmitoylation 
governs the spatial organization of NCX1 in the cell; 
palmitoylation-depalmitoylation cycle could tune the shuttle of the 
exchanger between plasma membrane and “palmitoylating” 
compartments. 
3.4. Limitations 
Although experimental conditions were optimised to minimise non- 
specific binding, we acknowledge that overexpressed integral mem-
brane proteins such as zDHHC-PATs can be susceptible to non-specific 
affinity purification. As such, we cannot rule out the possibility that 
some zDHHC-PATs co-purify non-specifically with our NCX1 peptide. 
Notwithstanding this point, our functional and imaging experiments 
clearly support the concept that NCX1 is palmitoylated by multiple 
zDHHC-PATs in multiple cellular compartments. 
In this investigation we focussed entirely on NCX1 palmitoylation 
and depalmitoylation mechanisms in HEK cells. The overlap between 
the repertoire of zDHHC-PATs expressed in cardiac muscle is substantial 
[41,42]. We have already established that APT1 but not APT2 mediates 
NCX1 depalmitoylation in both HEK cells and cardiac muscle [14]. 
While we cannot rule different cellular mechanisms controlling NCX1 
palmitoylation in cardiac muscle, we suggest the principals governing 
NCX1 palmitoylation identified in this study are broadly applicable to 
other cell types. 
3.5. Conclusion 
Palmitoylation is a critical process for physiological regulation of 
NCX1. Here we bring an important aspect into NCX1 palmitoylation by 
defining its molecular identity. Results of this study could possibly pave 
the way for new molecular/pharmacological strategies targeting the 
NCX1 palmitoylation/depalmitoylation machinery. As we now know 
that zDHHC-PATs and APT1 physically interact with NCX1 at amphi-
pathic ɑ-helix, manipulating the availability of this region for binding of 
palmitoylating and depalmitoylating enzyme would be helpful to tune 
NCX1 physiology. More broadly, this investigation specifically supports 
the concept of ‘local palmitoylation’. Several zDHHC-PATs localised in 
different subcellular compartments are clearly capable of palmitoylating 
NCX1. We suggest that a similar principal will apply to numerous other 
palmitoylated integral membrane proteins as they move through the 
secretory pathway. 
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4. Methods 
4.1. Cell lines, Plasmids and transfection 
HEK293 cells and HEK293 derived FT293 cells stably expressing 
Golgi- (Golgin84), ER- (Ii) hook were generated using Flp-In T-Rex 
System (Invitrogen). Plasmids expressing YFP tagged full length NCX1 
[20], YFP tagged NCX1 fragments covering the regions of NCX1 intra-
cellular loop and YFP tagged NCX1 with M744 P/H745 P/F746 P or 
F746E/F750E mutations [18,19] were described previously. Golgi 
marker; mcherry tagged Grasp65, and ER marker; DsER-red, were used 
to identified co-localization with these organelles [15]. CFP tagged- 
APT1 and APT2 plasmids were a kind gift from Prof Michael J. Shipston 
(University of Edinburgh). Transfection of plasmid constructs was ach-
ieved using Lipofectamin 2000 (Invitrogen) according to manufacturer’s 
instructions. 
4.2. Palmitoylation assays 
Resin-assisted capture of acylated proteins (Acyl-RAC) was per-
formed to purify palmitoylated proteins as described in detail elsewhere 
[15,18,19]. Free cysteine residues were first blocked with MMTS, then 
thioester bonds were cleaved with neutral hydroxylamine (HA). Pal-
mitoylation level of NCX1 is calculated and presented as the amount of 
palmitoylated NCX1 purified relative to its abundance in the corre-
sponding unfractionated cell lysate. 
To measure palmitoylation site occupancy we used a PEGylation 
assay that exchanges palmitates for a 5 kDa PEG molecule [43]. Briefly, 
free cysteines were alkylated with maleimide, then previously palmi-
toylated cysteines revealed with neutral hydroxylamine and PEGylated 
with 5 kDa methoxypolyethylene glycol maleimide. 
4.3. Peptide pull-down assay 
HEK293 cells were transfected with HA tagged zDHHC isoforms. 
Following 24 h expression of zDHHC-PATs, cells were lysed and solu-
bilised in lysis buffer; 2 mg/mL C12E10 supplemented with protease 
inhibitors for 30 min at 4 ◦C. Lysates were first precleared by incubating 
with equilibrated streptavidin-beads, then interacting zDHHC-PATs 
with NCX1 were pulled down using biotinylated NCX1 peptide (Alta 
Biosciences); corresponds to residues between 740 and 756 
(NCX1740–756), as described elsewhere [14] and analysed by western 
blot. 
4.4. Retention using selective hook (RUSH) system 
Retention using selective hook (RUSH) system described previously 
[28] was adapted based on the aim of our investigation. Briefly, our 
RUSH system consists of two fundamental components; Golgi- (Gol-
gin-84) or ER- (Ii; a type II protein) resident hook and NCX1266Y-SBP 
reporter (Streptavidin Binding Peptide (SBP) fused to full length NCX1 
tagged with YFP at 266 position). Golgin-84 or Ii were fused to strep-
tavidin and tagged with the hemagglutinin (HA) tag, and stably 
expressed in HEK293 derived FT293 cells using Flp-In T-Rex System 
(Invitrogen). SBP was fused to NCX1266Y using In-Fusion cloning 
(TakaraBio Inc.) and expressed in either Golgi or ER hook stably 
expressing cells. 
4.5. Confocal microscopy and image analysis 
Confocal imaging was performed on HEK293 cells, Golgi- and ER- 
hook stable cells. 24− 48 h after transfection with the plasmids, cells 
were fixed in 4% PFA for 10 min at room temperature. DNA of the cells 
were counter-stained with Hoechst to locate the nucleus, where it is 
indicated. Confocal images were captured with Zeiss LSM880 with 
Airyscan confocal microscopy. Diode (405− 430 nm), Argon (458 nm, 
488 nm, 514 nm) and Hene594 (594 nm) lasers were used for detecting 
blue (Hoechst or CFP), green (YFP) and red (DsRed or mcherry). 
Colocalization of NCX1 with Golgi- and ER- markers were analysed 
using Coloc2 macro in Fiji [44]. To quantify the area where NCX1 is 
populated, original images were first thresholded then the highlighted 
areas were calculated and presented as the percentage of total cell-area 
for each cell. 
4.6. Statistics 
Data are presented as mean ± standard error of the mean (SEM). 
Quantitative differences between groups were calculated by students’ t- 
test using GraphPad Prism. Information about sample size, means and 
SEM and p-values can be found in Figure legends. 
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